Ayça Erşen Danyeli

Ayça Erşen Danyeli

Auto-generated profile, based on publicly available information

Ayça Erşen Danyeli

Department of Medical Pathology Acibadem University Istanbul Turkey

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

5 September 2023 in Journal of Cutaneous Pathology
Verified
Journal Article
Closed access
CDCuyan Demirkesen
Cuyan Demirkesen
ADAyça Erşen Danyeli
Ayça Erşen Danyeli
PYPelin Yıldız
Pelin Yıldız
SESümeyre Seda Ertekin
Sümeyre Seda Ertekin
BYBerkhan Yılmaz
Berkhan Yılmaz
Armita BahramiArmita Bahrami
Armita Bahrami

4 July 2023 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
BTBahattin Tanrıkulu
Bahattin Tanrıkulu
AYAhmet Harun Yaşar
Ahmet Harun Yaşar
CCCengiz Canpolat
Cengiz Canpolat
FÇFunda Çorapçıoğlu
Funda Çorapçıoğlu
ETEvrim Tezcanli
Evrim Tezcanli
MÖM. Memet Özek
M. Memet Özek

20 November 2021 in Diagnostic and Interventional Radiology
Verified
Journal Article
Closed access
IYİbRahim Önder Yeniçeri
İbRahim Önder Yeniçeri
MYMehmet Erdem Yıldız
Mehmet Erdem Yıldız
KÖKoray Özduman
Koray Özduman
ADAyça Erşen Danyeli
Ayça Erşen Danyeli
MPM. Necmettin Pamir
M. Necmettin Pamir
ADAlp Dincer
Alp Dincer
The reliability and reproducibility of T2-weighted imaging/fluid-attenuated inversion recovery (T2/FLAIR) mismatch were investigated in the diagnosis of isocitrate dehydrogenase (IDH) mutant astrocytoma between WHO grade II and III diffuse hemispheric gliomas. WHO grade II and grade III diffuse hemispheric gliomas (n=133) treated in our institute were included in the study. Pathological findings and molecular markers of the cases were reviewed with the criteria of WHO 2016. The finding of mismatch between T2-weighted and FLAIR images in preoperative magnetic resonance imaging (MRI) of the cases was evaluated by two different radiologists. The readers reviewed MRIs independently, blinded to the histopathologic diagnosis or molecular subset of tumors. The cases were classified as IDH-mutant astrocytoma, oligodendroglioma and IDH-wildtype (IDH-wt) astrocytoma according to molecular and genetic features. T2/FLAIR mismatch positivity was observed in 46 patients (34.6%). T2/FLAIR mismatch positivity was observed in 42 of 75 IDH-mutant astrocytomas (56%) and 4 of 43 oligodendrogliomas (9.30%), while it was not seen among IDH-wt astrocytomas (0/15, 0%). The T2/FLAIR mismatch ratio was significantly different between IDH-mutant astrocytomas (WHO grade II and grade III) and oligodendrogliomas (chi-square, p <0.05). The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of T2/FLAIR mismatch in predicting IDH-mutant astrocytomas were 58.7%, 90.7%, 91.7%, 61.4%, and 70.3% respectively. Radiologist 1 diagnosed T2/FLAIR mismatch in 48 of 133 cases (36.1%) and Radiologist 2 in 66 of 133 cases (49.6%). The interrater agreement for the T2/FLAIR mismatch sign was 0.61 (p <0.05), 95% CI (0.55, 0.67). T2/FLAIR mismatch appears to be an important MRI finding in distinguishing IDH-mutant astrocytomas from other diffuse hemispheric gliomas. However, it should be kept in mind that T2/FLAIR mismatch sign can be seen in a minority of oligodendrogliomas besides IDH-mutant astrocytomas.

10 January 2022 in Brain Pathology
Verified
Journal Article
Open access
PDF file
LCLokman Cevik
Lokman Cevik
MLMarilyn Vazquez Landrove
Marilyn Vazquez Landrove
MAMehmet Tahir Aslan
Mehmet Tahir Aslan
VKVasilii Khammad
Vasilii Khammad
FGFrancisco Jose Garagorry Guerra
Francisco Jose Garagorry Guerra
JOJosé Javier Otero
José Javier Otero
Aims: Resource‐strained healthcare ecosystems often struggle with the adoption of the World Health Organization (WHO) recommendations for the classification of central nervous system (CNS) tumors. The generation of robust clinical diagnostic aids and the advancement of simple solutions to inform investment strategies in surgical neuropathology would improve patient care in these settings.Methods: We used simple information theory calculations on a brain cancer simulation model and real‐world data sets to compare contributions of clinical, histologic, immunohistochemical, and molecular information. An image noise assay was generated to compare the efficiencies of different image segmentation methods in H&E and Olig2 stained images obtained from digital slides. An auto‐adjustable image analysis workflow was generated and compared with neuropathologists for p53 positivity quantification. Finally, the density of extracted features of the nuclei, p53 positivity quantification, and combined ATRX/age feature was used to generate a predictive model for 1p/19q codeletion in IDH‐mutant tumors.Results: Information theory calculations can be performed on open access platforms and provide significant insight into linear and nonlinear associations between diagnostic biomarkers. Age, p53, and ATRX status have significant information for the diagnosis of IDH‐mutant tumors. The predictive models may facilitate the reduction of false‐positive 1p/19q codeletion by fluorescence in situ hybridization (FISH) testing.Conclusions: We posit that this approach provides an improvement on the cIMPACT‐NOW workflow recommendations for IDH‐mutant tumors and a framework for future resource and testing allocation.

24 June 2024 in American Journal of Neuroradiology
Verified
Journal Article
Closed access
PDF file
MMMikael Mir
Mikael Mir
NMNathaniel P. Miller
Nathaniel P. Miller
MWMatthew White
Matthew White
WEWendy Elvandahl
Wendy Elvandahl
ADAyca Ersen Danyeli
Ayca Ersen Danyeli
CÖCan Özütemiz
Can Özütemiz
BACKGROUND AND PURPOSE: A cleft-like non-enhancing hypointensity was observed repeatedly in the pituitary gland at the adenohypophysis/neurohypophysis border on contrast-enhanced 3D-Fat-Saturated T1-MPRAGE (C+3D-FS-T1 MPRAGE) using clinical 7T MRI. Our primary goal is to assess the prevalence of this finding. The secondary goals are to evaluate the frequency of other incidental pituitary lesions, MRI artifacts, and their effect on pituitary imaging on the C+3D-FS-T1 MPRAGE at 7T. MATERIALS AND METHODS: 100 patients who underwent 7T neuroimaging between 10/27/2021 and 8/10/23 were included. Each case was evaluated for cleft-like pituitary hypointensity, pituitary masses, and artifacts on C+3D-FS-T1 MPRAGE. Follow-up exams were evaluated if present. The average prevalence for each finding was calculated, as were descriptive statistics for age and sex. RESULTS: A cleft-like hypointensity was present in 66% of 7T MRIs. There were no significant differences between the "cleft-like present" and "cleft-like absent" groups regarding sex (P = .39) and age (P = .32). The cleft-like hypointensity was demonstrated in follow-up MRIs in 3/3 patients with 7T, 1/12 with 3T, and 1/5 with 1.5T. A mass was found in 22%, while 75% had no mass, and 3% were indeterminate. A mass was found in 18 (27%) of the "cleft-like present" and 4 (13%) of the "cleft-like absent" groups. The most common mass types were Rathke cleft cyst (RCC) in 7 (31.8%) patients, "RCC vs. entrapped CSF" in 6 (27.3%), and microadenoma in 6 (22.2%) in the "cleft-like present" group. There were no significant differences in the mass types between the "cleft-like present" and "cleft-like absent" groups (P = .23). Susceptibility and/or motion artifacts were frequent in general using C+3D-FS-T1 MPRAGE (54%). Artifact-free scans were significantly more frequent in the "cleft-like present" group (P =.03). CONCLUSIONS: A cleft-like non-enhancing hypointensity was frequently seen on the C+3D-FS-T1 MPRAGE at 7T MRI, which most likely represents a normal embryological Rathke9s cleft remnant and cannot be seen in lower field strength MRIs. Susceptibility and motion artifacts are common in the sella. They may affect image quality, and the artifacts at 7T may lead to an underestimation of the prevalence of Rathke cleft and other incidental findings. ABBREVIATIONS: C+3D-FS-T 1MPRAGE = Contrast-Enhanced 3D-Fat-Saturated T1-Magnetization Prepared Rapid Gradient Echo Imaging; RCC = Rathke9s Cleft Cyst.